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more recently experienced (similar global score).
However, the age at the time of diagnosis and the level of
incapacity experienced was related (p = 0.015). The
younger the patient is at which psoriasis is diagnosed the
higher the level of handicap is, particularly on the “every-
day” and “leisure” scores.
CONCLUSION: These results highlight the value of
appropriate and relevant psychological and medical 
environment for children suffering from psoriasis.
PES10
THE PSORIASIS MANAGEMENT DURATION
INDUCED DIFFERENCES IN THE DISABILTY’S
REPERCUSSION
Taieb C, Myon E
PharmacoEconomics Programs, bioMérieux-Pierre Fabre,
Boulogne Billancourt, France
Psoriasis is a chronicle disease, which concerns 4.7% of
the French population. Although it does not shorten life
it has major consequences on patients’ daily life because
of the damage to the body image.
OBJECTIVE: The purpose of this study is to report 
preliminary ﬁndings of perceived disability in patients
with psoriasis.
METHOD: SPOT is a longitudinal, prospective, obser-
vational, programme. 2000 patients with mild to moder-
ate psoriasis will be recruited. (1000 Chronic Psoriasis
Patient & 1000 New Psoriasis Patient). The Psoriasis 
Disability Index [PDI] (Finlay AY et al 1987) and the SF
12 are evaluated every 3 months.
RESULTS: The preliminary results concern the analysis
of the ﬁrst 413 PDI scales completed at the inclusion visit.
The mean PDI score of the chronic psoriasis patients
(CPP) (n = 215) was 15,2 (sd 13,2) and the mean PDI
score of the new psoriasis patients (NPP) (n = 198) was
10,4 (sd 11,7) (p < 0.0001). When the sub-group of
retired and housewife patients was analysed there was no
difference in the scores between the CPP and NPP.
However, the sub-group consisting of salaried employees,
unemployed and sick leave patients showed a clear 
difference, mean PDI of CPP 14,4 (n = 149) compared to
NPP mean PDI = 9,7 (n = 158) (p = 0.0003). When all
questionnaires were analysed the “active population” are
less disabled than the “inactive group” (p < 0.05) and this
difference is also seen within the NPP (p < 0.05).
CONCLUSION: This ﬁrst analysis demonstrates the 
disability experienced by CPP and its greater impact on
the “active population”. This study will enable long-term
monitoring of the evolution of patients’ psoriasis and the
perception of patients concerning their management.
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FUNCTIONAL LIMITATIONS IN THE US
ELDERLY POPULATION WITH VARYING LEVELS
OF VISUAL IMPAIRMENT
Lustig SP1, Shih YCT2, Prasad M2
1Pﬁzer Inc, Groton, CT, USA; 2MEDTAP International Inc,
Bethesda, MD, USA
OBJECTIVES: To examine the association between visual
impairment (VI) and functional limitations among the
elderly.
METHODS: Bivariate analyses were used to examine the
above associations. Data used in the analysis was the
Second Supplement on Aging (SOA II), a nationally rep-
resentative sample of the U.S. population aged 70 and
over in 1994. These cohort data of older Americans, col-
lected by the National Center of Health Statistics, are the
most recently released. VI identiﬁed from the data was
categorized into ﬁve forms: cataract, glaucoma, blindness
in one eye, blindness in both eyes, and trouble seeing 
even with glasses. Functional limitations were character-
ized by activities of daily living (ADLs), instrumental
activities of daily living (IADLs), and self-perceived health
status.
RESULTS: VI was found in 37.5% of persons aged 70
and over; among them 10% reported having more than
one form of VI. “Cataract” and “trouble seeing with
glasses”, alone or combined, accounted for approxi-
mately 68% of VI. On average, compared to the visually
unimpaired, the visually impaired group reported a sig-
niﬁcantly higher number of limitations in ADLs (diff =
0.52, P < 0.001) and IADLs (diff = 0.60, P < 0.001). A
signiﬁcantly higher proportion of the visually impaired
ranked their health status as poor (10.7% vs. 5.1%) and
a signiﬁcantly lower proportion reported “excellent”
(9.4% vs. 14.8%). Among the ﬁve forms of VI, the
average number of limitations in ADLs and IADLs were
highest among persons with blindness in both eyes (2.36
and 3.67, respectively), and were lowest in the glaucoma
group (0.86 and 0.89, respectively).
CONCLUSIONS: A positive and tangible association
existed between VI and more limited physical function-
ing as measured by ADLs and IADLs, and poorer self-
perceived health. Among the ﬁve forms of visual problems
examined, the most detrimental outcomes were found in
persons with blindness in both eyes.
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PES12
ANTIHISTAMINE UTILIZATION AND COSTS IN
PATIENTS WITH ATOPIC DERMATITIS
Kahler KH1, Pinkston P1, Freimark N2
1Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA; 2non-afﬁliated, Lakewood, NJ, USA
OBJECTIVE: Assess the antihistamine utilization and
associated costs in patients with atopic dermatitis (AD).
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METHODS: Data were extracted from Medstat’s 
MarketScan, a proprietary claims database, which
includes people who received pharmacy and medical 
beneﬁts from various managed care organizations. We
identiﬁed patients with continuous pharmacy coverage
and at least one pharmacy claim in 1999. The AD group
consisted of all those with at least one ICD-9 code for 
AD (691.8 or 692.9), and the control group consisted of
a 1 :1 match on age of those without AD. Antihistamine
use was deﬁned as at least one prescription during 1999.
The risk ratio and risk difference were calculated to
compare those with AD to the control group. Differences
in drug costs are estimated using the average AWP.
RESULTS: 40,998 people were identiﬁed with AD and at
least one pharmacy claim in 1999. 38.8% of AD patients
used antihistamines—13.6% had a prescription for a ﬁrst
generation product and 29.5% had a prescription for a
second generation product. Among the control group,
only 7.7% received an antihistamine prescription; 1.7%
for a 1st generation and 6.3% had a prescription for a
second generation product. The risk ratio for the more
costly 2nd generation products was 4.67 (95% CI: 4.48,
4.86), and for the 1st generation products, 7.83 (95% CI:
7.25, 8.45). The risk difference was 23.2% (95% CI:
22.7%, 23.7%) and 11.9% (95% CI: 11.5%, 12.2%),
respectively. The difference in per patient antihistamine
costs (AWP) was $40.47 for 2nd generation products and
$1.84 for 1st generation products.
CONCLUSIONS: Despite the lack of evidence support-
ing the use of antihistamines to treat patients with atopic
dermatitis, there is over a ﬁve-fold increase in use com-
pared to people without AD. This potentially inappro-
priate use translates to a substantial economic burden to
third party payers.
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EFFECTIVENESS OF MEDICAL INTERVENTIONS
IN PATIENTS WITH SYMPTOMS OF GERD—A
SYSTEMATIC REVIEW
Edwards S1, Wahlqvist P2
1AstraZeneca UK Ltd, Hertfordshire, UK; 2AstraZeneca R&D
Mölndal, Mölndal, Sweden
OBJECTIVES: To extract outcome data on the probabil-
ity of symptom resolution for acute drug treatment and
symptomatic relapse for long-term drug treatment in
patients with gastro-esophageal reﬂux disease (GERD),
by drug, dose and by patient category (non-endoscoped
GERD, endoscopy-veriﬁed reﬂux esophagitis and GERD
without esophagitis). The results were intended for use in
cost-effectiveness evaluations, where data on esophagitis
healing or remission have traditionally been used as a 
deﬁnition of success in the treatment of GERD.
METHODS: A systematic literature search for ran-
domised controlled trials of medical interventions for
GERD was carried out in September 2000 by a contract
research organisation, the Evidence Research Unit, UK.
The citations uncovered underwent a series of ﬁltering
steps for applicability and methodological quality. Where
possible, extracted data were pooled.
RESULTS: Very few of the 82 identiﬁed studies were
found to contain relevant data as a basis for the sympto-
matic probabilities required. Reliable pooled data were
only found for complete resolution of heartburn after 
4 weeks’ acute treatment with omeprazole 20mg od 
in patients with esophagitis (60.9%, n = 1,233) and in
patients with GERD without esophagitis (63.5%, n =
525, p > 0.05 for the difference between groups). Only
one study was identiﬁed concerning the 6-month proba-
bility of symptomatic relapse during no drug treatment
(i.e., not placebo) in GERD patients with esophagitis
(90%, n = 145) and without esophagitis (75%, n = 123,
p < 0.001 for the difference between groups).
CONCLUSIONS: Reliable symptomatic probabilities
intended for cost-effectiveness evaluations of medical
interventions for GERD could not be sufﬁciently obtained
in this systematic review of randomised controlled trials.
PGI2
THERAPEUTIC COMPARABILITY OF 
PROTON PUMP INHIBITORS
von Scheele B, Sherrill B, Richter A, Devlin P
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVE: This evidence-based review evaluates the
therapeutic comparability of ﬁve proton pump inhibitors
(PPIs): omeprazole, lansoprazole, pantoprazole, rabe-
prazole and esomeprazole for short-term treatment of
uncomplicated gastroesophageal reﬂux disease (GERD).
METHODS: A literature search identiﬁed 68 randomized
clinical trials comparing the PPIs to each other, to placebo
and/or to other anti-reﬂux treatments (histamine-2-
receptor [H2]-blockers). Evidence tables were compiled
for common outcomes and meta-analyses conducted. Efﬁ-
cacy was assessed on heartburn relief, esophageal healing,
overall GERD symptom relief, and withdrawals due to
lack of efﬁcacy. Safety was analyzed using withdrawals
due to adverse events, total adverse events, abdominal
pain, diarrhea, nausea and headache.
RESULTS: Meta-analyses found no differences between
the PPIs in heartburn relief, overall GERD symptom
relief, and withdrawals due to lack of efﬁcacy. The analy-
sis detected a statistically signiﬁcant efﬁcacy advantage 
of esomeprazole (20 and 40mg/day) over omeprazole 
(20mg/day) in acute erosive esophagitis healing rates.
Broad and speciﬁc safety outcomes were comparable
among the PPIs.
CONCLUSION: In the evidence collected here, the ﬁve
PPIs appear to be generally comparable for relief of
GERD symptoms. For treatment of acute erosive
esophagitis, both doses of esomeprazole were shown here
to be more beneﬁcial than omeprazole (20mg/day). In
terms of safety, the PPIs as a class have a remarkably low
incidence of side effects with few differences between
